Search
  1. Home
  2. Southern Africa
  3. South Africa

PMTCT continues despite Nevirapine controversy

    JOHANNESBURG

    A programme for the prevention of mother-to-child transmission of HIV (PMTCT) will continue in South Africa's Gauteng province, provincial health minister Gwen Ramokgopa has announced.

    Use of the anti-AIDS drug Nevirapine as a single dose in PMTCT programmes is currently under further research following claims by the Medicines Control Council (MCC) that the drug could create resistance in some HIV-positive expectant mothers.

    The MCC suggested that a combination of antiretrovirals be used for PMTCT instead and the Ministry of Health is expected to make a final recommendation to cabinet on future HIV/AIDS treatment methods as soon as the research is concluded.

    BuaNews, the government news agency, quoted Ramokgopa as saying, "The Gauteng Department of Health will use the national guidelines once the team has finalised them."

    This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

    Share this article

    Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

    We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

    Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

    Become a member of The New Humanitarian

    Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

    Join